SOLARANSESolara Active Pharma Sciences Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Thu, 6 Nov, 2025 · 11:09 IST

Solara posts Rs 10.10 crore quarterly loss as revenue declines

Going ConcernRevenue DeclinePat NegativeEbitda Margin CompressionResults View source PDFExplain this filing

SOLARA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-8.6%Reaction day
₹619.00
prior close
₹560.50
announcement price
In-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-1.7%-6.9% vs market
Pharmaceuticals peers, median of 156sector-1.1%-7.5% vs sector

On the reaction day the stock moved 6.9 pts less than Nifty Microcap 250 and 7.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.1
10m
-0.2
15m
-0.1
30m
+0.2
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-8.6-1.7-6.9-1.1-7.5
Next day
-8.6-1.3-7.3-1.4-7.2
2d
-10.9-1.7-9.2-2.0-8.9
3d
-12.7-1.9-10.8-2.3-10.5
4d
-10.5-1.0-9.5-1.2-9.3
5d
-7.4-1.1-6.3-1.5-5.9
1w
-7.7-0.6-7.1-1.7-6.0
15d
-16.4-3.0-13.3-4.3-12.1
1m
-12.2-8.1-4.1-6.7-5.4
2m
-8.2-4.8-3.4-5.1-3.2
3m
-25.0-9.1-15.9-8.9-16.2
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Quarterly consolidated revenue fell to Rs 313.54 crore from Rs 346.95 crore, and the company swung to a Rs 10.10 crore loss from Rs 8.01 crore profit. Half-year revenue was Rs 632.69 crore and profit Rs 0.42 crore. Net current liabilities exceeded current assets by Rs 72.69 crore. The Board prepared the accounts on the basis that operations will continue.

Likely market impact

Lower sales, the quarterly loss and weak liquidity are negative. Pending rights funding supports operations but could increase shareholder dilution.